Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service colorectal resection cases in Minnesota: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (230 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 2 | 1,068 | 49% |
| 2020 | 2 | 984 | 52% |
| 2021 | 3 | 1,065 | 56% |
| 2022 | 0 | 851 | 59% |
| 2023 | 2 | 872 | 62% |
| 2024 | 1 | 849 | 64% |
| 2025 from claims | – | 905 732–1,062 | 65% |
| 2026 forecast | – | 1,016 796–1,276 | 61% |
| 2027 forecast | – | 1,042 773–1,377 | 61% |
| 2028 forecast | – | 1,068 756–1,475 | 61% |
| 2029 forecast | – | 1,095 744–1,570 | 60% |
| 2030 forecast | – | 1,123 736–1,666 | 60% |
Laparoscopic and open colectomy and proctectomy; stapler, energy, and robotics call point. Professional codes (what the surgeon bills): CPT 44204, 44205, 44207, 44140, 44145, 44160, 45395, 45397; the hospital bills MS-DRG 329, 330, 331.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Minnesota; 1 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% inpatient hospital.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Illinois | 7 | 2,192−5.2%/yr | −5.2%/yr | 1.6 | 0% | 1,930 in 2030−2.1%/yr |
| Ohio | 8 | 1,916−5.8%/yr | −5.8%/yr | 1.8 | 0% | 2,040 in 2030+1.1%/yr |
| Michigan | 3 | 1,300−11%/yr | −11%/yr | 1.6 | 0% | 1,170 in 2030−1.7%/yr |
| Missouri | 6 | 1,232−5.9%/yr | −5.9%/yr | 2.0 | 0% | 1,250 in 2030+0.2%/yr |
| Indiana | 3 | 1,174−6.4%/yr | −6.4%/yr | 1.7 | 0% | 1,190 in 2030+0.2%/yr |
| Wisconsin | 1 | 955−4%/yr | −4%/yr | 1.7 | 0% | 1,070 in 2030+1.9%/yr |
| Kansas | 4 | 782−3.5%/yr | −3.5%/yr | 2.0 | 0% | 730 in 2030−1.1%/yr |
| Iowa | 3 | 615−5.1%/yr | −5.1%/yr | 1.4 | 0% | 570 in 2030−1.3%/yr |
| Nebraska | 2 | 506−3.8%/yr | −3.8%/yr | 2.0 | 0% | 480 in 2030−0.8%/yr |
| South Dakota | 1 | 271−6.1%/yr | −6.1%/yr | 2.1 | 0% | 320 in 2030+2.7%/yr |
| North Dakota | 0 | 196−4.4%/yr | −4.4%/yr | 2.0 | 0% | 230 in 2030+2.4%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Hernia repair | 18 | 2,581−3.2%/yr | −3.2%/yr | 6.11.0× | 8% | 3,830 in 2030+6.8%/yr |
| Cholecystectomy & appendectomy | 23 | 1,976−5.3%/yr | −5.3%/yr | 4.51.0× | 2% | 2,420 in 2030+3.5%/yr |
| Antireflux & hiatal hernia surgery | 3 | 341−4.9%/yr | −4.9%/yr | 0.81.0× | 0% | 500 in 2030+6.7%/yr |
| Breast reconstruction | 1 | 226−8.1%/yr | −8.1%/yr | 0.51.2× | 16% | 310 in 2030+5.1%/yr |
Colorectal resection in every state, and its device makers · Every procedure market in Minnesota · Every state · Compare with Illinois
Intuitive Surgical leads with 69% of company spending on these surgeons in 2025, −6 pts on 2024.
In 2025, 4 companies reported engagement with Minnesota’s surgeons worth $206K in consulting, speaking, meals and travel tied to these products, about $206K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 14 clearances and approvals in the category, 12 recalled product lines (1 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.